Clinical Trial Update: A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 study of ARC1905, an anti-C5 aptamer, for dry age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• ARC1905 (ARC1905)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Dry Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED